Skeletal muscle expression of adipose-specific phospholipase in peripheral artery disease.

Flow-limiting atherosclerotic lesions of arteries supplying the limbs are a cause of symptoms in patients with peripheral artery disease Musculoskeletal metabolic factors also contribute to the pathophysiology of claudication, which is manifest as leg discomfort that impairs walking capacity. Accordingly, we conducted a case-control study to determine whether skeletal muscle metabolic gene expression is altered in Calf skeletal muscle gene expression of patients with and healthy subjects was analyzed using microarrays. The top-ranking gene differentially expressed between duanyu1563 and controls (FDR < 0.001) was PLA2G16, which encodes adipose-specific phospholipase A2 (AdPLA) and is implicated in the maintenance of insulin sensitivity and regulation of lipid metabolism. Differential expression was confirmed by qRT-PCR; PLA2G16 was downregulated by 68% in patients with duanyu1563 (p < 0.001). Expression of Pla2g16 was then measured in control (db/+) and diabetic (db/db) mice that underwent unilateral femoral artery ligation. There was significantly reduced expression of Pla2g16 in the ischemic leg of both control and diabetic mice (by 51%), with significantly greater magnitude of reduction in the diabetic mice (by 79%). We conclude that AdPLA is downregulated in humans with duanyu1563 and in mice with hindlimb ischemia. Reduced AdPLA may contribute to impaired walking capacity in patients with duanyu1563 via its effects on skeletal muscle metabolism. Further studies are needed to fully characterize the role of AdPLA in duanyu1563 and to investigate its potential as a therapeutic target for alleviating symptoms of claudication.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}